Henlius established in 2010 is a global biopharmaceutical company with the vision to offer high-quality, affordable and innovative biologic medicines to patients worldwide with a focus on oncology, autoimmune diseases and ophthalmic diseases. Henlius has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle including R&D facilities in China and US, manufacturing China/EU GMP and commercialization in China. Henlius has 4 products launched in China, 1 in the European Union (EU), and 3 products coming to the US. Henlius has pro-actively built a diversified and high-quality product pipeline covering over 20 innovative monoclonal antibodies (mAbs) and has continued to explore immuno-oncology combination therapies with proprietary serplulimab (anti-PD-1 mAb) as backbone. Henlius has conducted over 50 clinical studies for 11 products and 8 combination therapies worldwide.
Ticker:
2696.HK
Exchange:
Hong Kong Exchanges and Clearing Limited
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
China
Year Founded:
2010
Main Therapeutic Focus:
Oncology
Lead Product in Development:
Biosimilar and Bioinnovative, including Serplulimab (anti-PD-1 mAb)
Development Phase of Primary Product:
Multiple Products in Market
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
